Literature DB >> 31524503

Circulating Plasma Biomarkers of Progressive Interstitial Lung Disease.

Shehabaldin Alqalyoobi1, Ayodeji Adegunsoye2, Angela Linderholm1, Cara Hrusch2, Claire Cutting1, Shwu-Fan Ma3, Anne Sperling2, Imre Noth3, Mary E Strek2, Justin M Oldham1,4.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 31524503      PMCID： PMC6961741          DOI： 10.1164/rccm.201907-1343LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  10 in total

1.  Clinical Utility of YKL-40 in Polymyositis/dermatomyositis-associated Interstitial Lung Disease.

Authors:  Hironao Hozumi; Tomoyuki Fujisawa; Noriyuki Enomoto; Ran Nakashima; Yasunori Enomoto; Yuzo Suzuki; Masato Kono; Masato Karayama; Kazuki Furuhashi; Akihiro Murakami; Naoki Inui; Yutaro Nakamura; Tsuneyo Mimori; Takafumi Suda
Journal:  J Rheumatol       Date:  2017-07-15       Impact factor: 4.666

2.  Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis.

Authors:  Thomas J Richards; Naftali Kaminski; Fred Baribaud; Susan Flavin; Carrie Brodmerkel; Daniel Horowitz; Katherine Li; Jiin Choi; Louis J Vuga; Kathleen O Lindell; Melinda Klesen; Yingze Zhang; Kevin F Gibson
Journal:  Am J Respir Crit Care Med       Date:  2012-01-01       Impact factor: 21.405

3.  Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis.

Authors:  Xiaoping Long; Xuan He; Shinichiro Ohshimo; Matthias Griese; Rafael Sarria; Josune Guzman; Ulrich Costabel; Francesco Bonella
Journal:  Eur Respir J       Date:  2017-02-23       Impact factor: 16.671

4.  Predicting survival across chronic interstitial lung disease: the ILD-GAP model.

Authors:  Christopher J Ryerson; Eric Vittinghoff; Brett Ley; Joyce S Lee; Joshua J Mooney; Kirk D Jones; Brett M Elicker; Paul J Wolters; Laura L Koth; Talmadge E King; Harold R Collard
Journal:  Chest       Date:  2014-04       Impact factor: 9.410

5.  Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis.

Authors:  Nicoline M Korthagen; Coline H M van Moorsel; Nicole P Barlo; Henk J T Ruven; Adrian Kruit; Michiel Heron; Jules M M van den Bosch; Jan C Grutters
Journal:  Respir Med       Date:  2011-01       Impact factor: 3.415

6.  A chemokine-driven positive feedback loop organizes lymphoid follicles.

Authors:  K M Ansel; V N Ngo; P L Hyman; S A Luther; R Förster; J D Sedgwick; J L Browning; M Lipp; J G Cyster
Journal:  Nature       Date:  2000-07-20       Impact factor: 49.962

7.  An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study.

Authors:  Toby M Maher; Eunice Oballa; Juliet K Simpson; Joanne Porte; Anthony Habgood; William A Fahy; Aiden Flynn; Philip L Molyneaux; Rebecca Braybrooke; Hrushikesh Divyateja; Helen Parfrey; Doris Rassl; Anne-Marie Russell; Gauri Saini; Elisabetta A Renzoni; Anne-Marie Duggan; Richard Hubbard; Athol U Wells; Pauline T Lukey; Richard P Marshall; R Gisli Jenkins
Journal:  Lancet Respir Med       Date:  2017-11-14       Impact factor: 30.700

8.  C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis.

Authors:  Louis J Vuga; John R Tedrow; Kusum V Pandit; Jiangning Tan; Daniel J Kass; Jianmin Xue; Divay Chandra; Joseph K Leader; Kevin F Gibson; Naftali Kaminski; Frank C Sciurba; Steven R Duncan
Journal:  Am J Respir Crit Care Med       Date:  2014-04-15       Impact factor: 21.405

9.  CXCR3/CXCL10 interactions in the development of hypersensitivity pneumonitis.

Authors:  Carlo Agostini; Fiorella Calabrese; Venerino Poletti; Guido Marcer; Monica Facco; Marta Miorin; Anna Cabrelle; Ilenia Baesso; Renato Zambello; Livio Trentin; Gianpietro Semenzato
Journal:  Respir Res       Date:  2005-02-22

10.  CXCL13 antibody for the treatment of autoimmune disorders.

Authors:  Ekaterina Klimatcheva; Tracy Pandina; Christine Reilly; Sebold Torno; Holm Bussler; Maria Scrivens; Alan Jonason; Crystal Mallow; Michael Doherty; Mark Paris; Ernest S Smith; Maurice Zauderer
Journal:  BMC Immunol       Date:  2015-02-12       Impact factor: 3.615
  10 in total
  8 in total

Review 1.  Update in Interstitial Lung Disease 2020.

Authors:  Anna J Podolanczuk; Alyson W Wong; Shigeki Saito; Joseph A Lasky; Christopher J Ryerson; Oliver Eickelberg
Journal:  Am J Respir Crit Care Med       Date:  2021-06-01       Impact factor: 21.405

2.  Can YKL-40 be used as a biomarker for interstitial lung disease?: A systematic review and meta-analysis.

Authors:  Xiang Tong; Yao Ma; Tao Liu; Zhenzhen Li; Sitong Liu; Guihui Wu; Hong Fan
Journal:  Medicine (Baltimore)       Date:  2021-04-30       Impact factor: 1.817

3.  Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis.

Authors:  Ayodeji Adegunsoye; Shehabaldin Alqalyoobi; Angela Linderholm; Willis S Bowman; Cathryn T Lee; Janelle Vu Pugashetti; Nandini Sarma; Shwu-Fan Ma; Angela Haczku; Anne Sperling; Mary E Strek; Imre Noth; Justin M Oldham
Journal:  Chest       Date:  2020-05-22       Impact factor: 9.410

4.  Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis.

Authors:  Willis S Bowman; Chad A Newton; Angela L Linderholm; Megan L Neely; Janelle Vu Pugashetti; Bhavika Kaul; Vivian Vo; Gabrielle A Echt; William Leon; Rupal J Shah; Yong Huang; Christine Kim Garcia; Paul J Wolters; Justin M Oldham
Journal:  Lancet Respir Med       Date:  2022-01-18       Impact factor: 102.642

Review 5.  Diagnostic and Therapeutic Applications of Extracellular Vesicles in Interstitial Lung Diseases.

Authors:  Abdulrahman Ibrahim; Ahmed Ibrahim; Tanyalak Parimon
Journal:  Diagnostics (Basel)       Date:  2021-01-07

6.  Myositis-specific Antibodies Identify A Distinct Interstitial Pneumonia with Autoimmune Features Phenotype.

Authors:  Julia Graham; Iazsmin Bauer Ventura; Chad A Newton; Cathryn Lee; Noelle Boctor; Janelle Vu Pugashetti; Claire Cutting; Elena Joerns; Habrinder Sandhu; Jonathan H Chung; Christine Kim Garcia; Michael Kadoch; Imre Noth; Ayodeji Adegunsoye; Mary E Strek; Justin M Oldham
Journal:  Eur Respir J       Date:  2020-07-16       Impact factor: 16.671

Review 7.  Biomarkers in Progressive Fibrosing Interstitial Lung Disease: Optimizing Diagnosis, Prognosis, and Treatment Response.

Authors:  Willis S Bowman; Gabrielle A Echt; Justin M Oldham
Journal:  Front Med (Lausanne)       Date:  2021-05-10

Review 8.  Interstitial Lung Disease in Connective Tissue Disease: A Common Lesion With Heterogeneous Mechanisms and Treatment Considerations.

Authors:  Tihong Shao; Xiaodong Shi; Shanpeng Yang; Wei Zhang; Xiaohu Li; Jingwei Shu; Shehabaldin Alqalyoobi; Amir A Zeki; Patrick S Leung; Zongwen Shuai
Journal:  Front Immunol       Date:  2021-06-07       Impact factor: 7.561
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.